These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12878377)

  • 1. Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?
    Lasaridis AN; Sarafidis PA
    Am J Hypertens; 2003 Aug; 16(8):689-97. PubMed ID: 12878377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive agents for preventing diabetic kidney disease.
    Lv J; Perkovic V; Foote CV; Craig ME; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2012 Dec; 12():CD004136. PubMed ID: 23235603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
    Hommel E
    J Hypertens Suppl; 1989 Sep; 7(7):S49-51. PubMed ID: 2575661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Protective effect of antihypertensive agents on renal insufficiency (REIN, RENAAL, IDNT, AASK, etc)].
    Tsuchida H; Kimura K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():617-22. PubMed ID: 15171445
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy.
    Cziraky MJ; Mehra IV; Wilson MD; Bakris GL
    Ann Pharmacother; 1996; 30(7-8):791-801. PubMed ID: 8826564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive drugs and diabetic nephropathy.
    Mehler PS; Schrier RW
    Curr Hypertens Rep; 1999; 1(2):170-7. PubMed ID: 10981062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria.
    Donnelly R; Molyneaux LM; Willey KA; Yue DK
    Am J Cardiol; 1996 Feb; 77(6):26B-30B. PubMed ID: 8848991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of diabetic nephropathy].
    Barna I
    Orv Hetil; 2003 Jan; 144(4):165-72. PubMed ID: 12621814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression.
    Strippoli GF; Craig MC; Schena FP; Craig JC
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S153-5. PubMed ID: 16565242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors.
    Brenner BM; Zagrobelny J
    Kidney Int Suppl; 2003 Feb; (83):S77-85. PubMed ID: 12864880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of chemical therapies for treating diabetic hypertension.
    Sarafidis PA; Alexandrou ME; Ruilope LM
    Expert Opin Pharmacother; 2017 Jun; 18(9):909-923. PubMed ID: 28480805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Tsalamandris C; Cooper ME
    Kidney Int; 1992 Apr; 41(4):904-11. PubMed ID: 1513112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on calcium antagonists and the kidney.
    Tobe S
    Curr Opin Nephrol Hypertens; 2003 May; 12(3):309-15. PubMed ID: 12698071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of antihypertensive prescription and associated blood pressure control in Japan.
    Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
    Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slowing the progression of renal disease in diabetic patients.
    Vivian EM; Goebig ML
    Ann Pharmacother; 2001 Apr; 35(4):452-63. PubMed ID: 11302410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.